Eyenovia to Participate in Multiple Upcoming Medical Meetings
October 02 2019 - 8:30AM
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose
therapeutics utilizing its patented piezo-print delivery
technology, today announced that it will be presenting at multiple
eyecare meetings in October. Experts in optometry and ophthalmology
as well as Eyenovia’s management team plans to highlight the
Company’s late stage clinical pipeline, data from its MicroStat
Phase III MIST-1 and MIST-2 studies for pharmacologic mydriasis, as
well as new usability data generated from its MicroPine Phase III
study in pediatric progressive myopia.
“We are very excited to participate alongside
our optometric and ophthalmic partners in several major upcoming
eyecare meetings this fall and look forward to sharing further
results from our MicroStat Phase III MIST-1 and MIST-2 studies with
other industry leaders,” commented Dr. Sean Ianchulev,
Eyenovia’s Chief Executive Officer and Chief Medical
Officer. “In addition, we look forward to presenting
compelling usability data from our ongoing MicroPine Phase III
Chaperone study in pediatric progressive myopia, which we believe
further supports the use of high precision microdosing for topical
ocular therapies.”
Details for the meetings are below:
Meeting: Interventional Glaucoma
Congress
Panel Title: Drug Delivery
Targets: Principles, Goals, ChallengesPresenter:
Dr. Sean Ianchulev, CEO & CMODate/Time:
Friday, October 4, 2019 at 10:05 a.m. ETLocation:
The Westin New York at Times Square, New York, NY
Meeting: Ophthalmology Innovation Summit
at the American Academy of Ophthalmology (OIS@AAO)
Session Title: Innovation
Showcase 2Presenter: Dr. Sean Ianchulev, CEO &
CMODate/Time: Thursday, October 10, 2019 at
10:11-10:18 a.m. PTLocation: Hilton San Francisco
Union Square, San Francisco, CA
Meeting: American Academy of
Ophthalmology (AAO)
Date: Saturday, October 12 -
Tuesday, October 15, 2019Booth:
#6324Location: Moscone Center, San Francisco,
CA.
Meeting: American Academy of Optometry’s
3rd World Congress of Optometry (AAOpt)
Presentation: American Academy
of Optometry Professional Press
ConferencePresenter: Mark A. Bullimore, MD, Dean
of the Southern California College of Optometry at Marshall B.
Ketchum University and a Fellow of the American Academy of
Optometry (AAOpt)Date/Time: Wednesday, October 23,
2019 at 7:30 – 9:30 a.m. ETRoom: W240AB, Level
IILocation: Orange County Convention Center,
Orlando, FL
Poster: Clinical Evaluation of
a Micro-dosed Fixed Combination Phenylephrine 2.5%-Tropicamide 1%
Ophthalmic Solution for Dilation of the Pupil in Two Randomized,
Controlled Phase 3 Trials (MIST-1 &
MIST-2)Presenter: Tom Walters, Md, Keystone
Research, LtdDate/Time: Friday, October 25, 2019
at 1:00-3:00 p.m. ETBoard: #193 in Exhibit Hall
WD1Location: Orange County Convention Center,
Orlando, FL
About EyenoviaEyenovia, Inc.
(NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical
company developing a pipeline of microdose therapeutics utilizing
its patent piezo-print delivery technology. Eyenovia’s pipeline is
currently focused on the late-stage development of microdosed
medications for mydriasis, myopia progression, glaucoma and other
eye diseases. For more information please visit
www.eyenovia.com.
Company Contact:Eyenovia,
Inc.John GandolfoChief Financial
Officerjgandolfo@eyenoviabio.com
Investor Contact:Tram Bui /
Alexander LoboThe Ruth GroupPhone:
646-536-7035/7037tbui@theruthgroup.com / alobo@theruthgroup.com
Media Contact:The Ruth
GroupKirsten Thomas508-280-6592kthomas@theruthgroup.com
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Sep 2023 to Sep 2024